Concluded a technical evaluation agreement for DDS aptamer technology. Consideration of 53,000 million USD will be received and is expected to be recorded as business revenue in the fiscal year ending March 2027. A revision to earnings guidance has already been announced.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4591","jir_company_name":"Ribomic Inc.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-10-20","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/4591-20261020-01.pdf","jir_short_summary":"Concluded a technical evaluation agreement for DDS aptamer technology. Consideration of 53,000 million USD will be received and is expected to be recorded as business revenue in the fiscal year ending March 2027. A revision to earnings guidance has already been announced.","jir_summary":"### Summary of the News\nRibomic Inc. announced that it has entered into a technical evaluation agreement with an overseas biotechnology company regarding its DDS aptamer technology. Consideration of 53,000 million USD is expected to be received. The agreement is for the purpose of technical evaluation and does not promise a business alliance or joint research. This is positioned as the sixth initiative in the drug discovery support business.\n\n### Future Outlook and Impact\nThe consideration under this agreement is expected to be recorded as business revenue in the fiscal year ending March 2027. The counterparty will not be disclosed due to a confidentiality agreement, and the impact of exchange rate fluctuations may vary at the time of recognition. This initiative is regarded as important for promoting future R&D and creating new business opportunities.","jir_financial_highlights":"Consideration: 53,000 million USD (Unknown)\nEarnings Outlook: To be recorded as business revenue in the fiscal year ending March 2027 (Unknown)\nExchange Rate Reference Date: Indicative rate as of October 19: 157.95 yen (Unknown)","jir_category":"","jir_hashtags":"#Ribomic, #DDSAptamer, #TechnicalEvaluationAgreement","jir_key_figures":"53,000 million USD: Consideration\nFiscal year ending March 2027: Expected to be recorded as business revenue\n157.95 yen: Indicative rate (as of October 19)","jir_meta_title":"Ribomic Inc. Concludes Technical Evaluation Agreement for DDS Aptamer Technology | October 2026","jir_meta_description":"Ribomic Inc. has concluded a technical evaluation agreement with an overseas company for its DDS aptamer technology. Consideration is 53,000 million USD, expected to be recorded as revenue in the fiscal year ending March 2027. Supports future R&D and business expansion.","jir_og_title":"Ribomic Inc. Concludes Technical Evaluation Agreement for DDS Aptamer Technology","jir_og_description":"Concluded an evaluation agreement for DDS aptamer technology with an overseas company. Consideration of 53,000 million USD is scheduled to be recorded, expected as revenue in the fiscal year ending March 2027.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":60243,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"general_ir","footnotes":""},"sector":[],"importance":[],"class_list":["post-132857","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n